February 28, 2019
TOKYO, JAPAN - February 28, 2019 - Terumo Corporation (TSE: 4543) today announced that it will begin selling the Dexcom G4™ PLATINUM Continuous Glucose Monitoring System in Japan. U.S.-based DexCom, Inc., manufactured the product and Terumo has the right to distribute it exclusively in Japan.
The Dexcom G4™ PLATINUM is a medical system for people with diabetes that continuously monitors the glucose level in the interstitial fluid of subcutaneous tissues. Dexcom is a global market leader in real-time CGM, and its products stand out for their high accuracy and a safety mechanism that automatically alerts the user when the level of blood glucose is too low or too high.
Diabetes may lead to: loss of patients' eyesight, kidney disease, myocardial infarction or stroke. Terumo positions the launch of the CGM as an important milestone in contributing to diabetes therapy. The company plans to commence nationwide sales of Dexcom's CGM with Terumo's self-monitoring blood glucose system, and Japan's first tubing-free insulin patch pump. Meanwhile, Terumo will continue to launch Dexcom's next-generation CGM systems as each new model becomes available in Japan.
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers, with over US$5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices, including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician-office use. Terumo contributes to society by providing valued products and services to the healthcare market, and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.
(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.